Trials / Terminated
TerminatedNCT01698944
Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency
Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 12 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily |
Timeline
- Start date
- 2001-05-16
- Primary completion
- 2002-11-18
- Completion
- 2002-11-18
- First posted
- 2012-10-03
- Last updated
- 2017-02-27
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT01698944. Inclusion in this directory is not an endorsement.